Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2)
Gérald Simonneau(Inserm), Eckhard Mayer(Kerckhoff Klinik), Marius M. Hoeper(Medizinische Hochschule Hannover), Andrea Maria D’Armini(University of Pavia), Pablo Colorado, Arno Fritsch(Bayer (United States)), Nick H. Kim(University of California San Diego), Friedrich Grimminger(Justus-Liebig-Universität Gießen), Martin R. Wilkins(Hammersmith Hospital), Chen Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Pavel Jansa(General University Hospital in Prague), Neil Davie(Bayer (Germany))
Cited by 309
Related Papers
RETRACTED: 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study
|The Lancet|2021|4.3k
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
|The Lancet|2020|3.7k
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
|European Heart Journal|2022|3.6k
Definitions and Diagnosis of Pulmonary Hypertension
|Journal of the American College of Cardiology|2013|1.8k